Introduction:The difficulty in treating lung adenocarcinoma(LUAD)is caused by a shortage of knowledge about the biological mechanisms and a lack of treatment choices.Objectives:The aim of this study was to identify a ...Introduction:The difficulty in treating lung adenocarcinoma(LUAD)is caused by a shortage of knowledge about the biological mechanisms and a lack of treatment choices.Objectives:The aim of this study was to identify a valuable molecular target for the treatment of LUAD.Methods:Using multiple databases,we screened for hub genes in LUAD using Cytoscape and explored the expression and prognosis of DLG associated protein 5(DLGAP5)in LUAD.We investigated the genetic variation,functional enrichment,and epigenetic activity of DLGAP5.Furthermore,we evaluated the relationship between the tumor microenvironment(TME)and DLGAP5.Results:Our study identified 10 hub genes in LUAD:CDC45,KIAA0101,DLGAP5,CDT1,NCAPG,CCNB1,CDCA5,CDC20,KIF11,and AURKA.We discovered that DLGAP5 was overexpressed and associated with poor prognosis in LUAD.DLGAP5 exhibited an overall genetic variation frequency of 2%,and its DNA promoter was hypomethylated in LUAD(p<0.05).The expression of DLGAP5 in LUAD showed a positive correlation with the majority of N6-methyladenosine(m6A)-methylation genes.Additionally,DLGAP5 was primarily associated with the cell cycle in LUAD.Notably,there was a significant favorable association between DLGAP5 and CD274,CTLA4,HAVCR2,and LAG3 in LUAD.Conclusion:DLGAP5 may be a therapeutic target for LUAD,as it affects cancer cells proliferation and development through the regulation of cell-cycle checkpoints and modulation of immune cell infiltration and immune checkpoints in the TME.展开更多
Background:The survival benefits of pulmonary metastasectomy(PM)in colorectal cancer(CRC)patients with pulmonary metastasis remain controversial.This study aimed to assess the survival effect of PM on CRC patients wit...Background:The survival benefits of pulmonary metastasectomy(PM)in colorectal cancer(CRC)patients with pulmonary metastasis remain controversial.This study aimed to assess the survival effect of PM on CRC patients with pulmonary metastasis.Methods:Data from CRC patients with pulmonary metastasis were collected from the Surveillance,Epidemiology,and End Results database between 2010 and 2020.A 1:1 propensity score matching(PSM)analysis was employed to minimize heterogeneity between the groups.Kaplan-Meier analysis was performed to evaluate the overall survival(OS)of CRC patients with pulmonary metastasis who underwent PM.Results:A total of 1,399 CRC patients with pulmonary metastasis were included;140 patients and 1,259 patients underwent PM and did not,respectively.After PSM,there were 140 patients in each group.Patients who underwent PM demonstrated a longer median OS than those who did not,in both the overall cohort and the PSM cohort.In the PSM cohort,the median OS was 51 months(95%confidence interval[CI],45-64 months)for CRC patients with pulmonary metastasis who underwent PM and 36 months(95%CI,31-42 months)for those who did not undergo PM.Additionally,Cox proportional hazard models indicated that PM was a significant protective factor for OS in CRC patients with pulmonary metastasis(hazard ratio:0.57;95%CI,0.41-0.80,P<0.01).Conclusion:PM prolongs the survival of CRC patients with pulmonary metastasis.展开更多
基金funded by the supporting funds for scientific research of the Sixth Affiliated Hospital,Sun Yat-sen University(P20200217202404781).
文摘Introduction:The difficulty in treating lung adenocarcinoma(LUAD)is caused by a shortage of knowledge about the biological mechanisms and a lack of treatment choices.Objectives:The aim of this study was to identify a valuable molecular target for the treatment of LUAD.Methods:Using multiple databases,we screened for hub genes in LUAD using Cytoscape and explored the expression and prognosis of DLG associated protein 5(DLGAP5)in LUAD.We investigated the genetic variation,functional enrichment,and epigenetic activity of DLGAP5.Furthermore,we evaluated the relationship between the tumor microenvironment(TME)and DLGAP5.Results:Our study identified 10 hub genes in LUAD:CDC45,KIAA0101,DLGAP5,CDT1,NCAPG,CCNB1,CDCA5,CDC20,KIF11,and AURKA.We discovered that DLGAP5 was overexpressed and associated with poor prognosis in LUAD.DLGAP5 exhibited an overall genetic variation frequency of 2%,and its DNA promoter was hypomethylated in LUAD(p<0.05).The expression of DLGAP5 in LUAD showed a positive correlation with the majority of N6-methyladenosine(m6A)-methylation genes.Additionally,DLGAP5 was primarily associated with the cell cycle in LUAD.Notably,there was a significant favorable association between DLGAP5 and CD274,CTLA4,HAVCR2,and LAG3 in LUAD.Conclusion:DLGAP5 may be a therapeutic target for LUAD,as it affects cancer cells proliferation and development through the regulation of cell-cycle checkpoints and modulation of immune cell infiltration and immune checkpoints in the TME.
基金supported by National Key Clinical Discipline and the National Natural Science Foundation of China[grant number 82102955]the Guangzhou Basic Research Project[grant number 202201011326]the GuangDong Basic and Applied Basic Research Foundation[grant number 2024A1515220062]。
文摘Background:The survival benefits of pulmonary metastasectomy(PM)in colorectal cancer(CRC)patients with pulmonary metastasis remain controversial.This study aimed to assess the survival effect of PM on CRC patients with pulmonary metastasis.Methods:Data from CRC patients with pulmonary metastasis were collected from the Surveillance,Epidemiology,and End Results database between 2010 and 2020.A 1:1 propensity score matching(PSM)analysis was employed to minimize heterogeneity between the groups.Kaplan-Meier analysis was performed to evaluate the overall survival(OS)of CRC patients with pulmonary metastasis who underwent PM.Results:A total of 1,399 CRC patients with pulmonary metastasis were included;140 patients and 1,259 patients underwent PM and did not,respectively.After PSM,there were 140 patients in each group.Patients who underwent PM demonstrated a longer median OS than those who did not,in both the overall cohort and the PSM cohort.In the PSM cohort,the median OS was 51 months(95%confidence interval[CI],45-64 months)for CRC patients with pulmonary metastasis who underwent PM and 36 months(95%CI,31-42 months)for those who did not undergo PM.Additionally,Cox proportional hazard models indicated that PM was a significant protective factor for OS in CRC patients with pulmonary metastasis(hazard ratio:0.57;95%CI,0.41-0.80,P<0.01).Conclusion:PM prolongs the survival of CRC patients with pulmonary metastasis.
